IMBiotechnologies
Manufacturing · Canada · 1-10 Employees
View Company Info for Free
Overview
Headquarters
9650 20 Ave NW, Edmonton, Alberta, T6N 1...Phone Number
(780) 945-6609Website
www.imbiotechnologies.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About IMBiotechnologies
IMBiotechnologies Ltd. is a Canadian medical device company based in Edmonton, Alberta, specializing in the commercialization of innovative products for embolotherapy. Their core technology focuses on treating solid malignant tumors and benign tumors, including liver cancer, kidney cancer, uterine fibroids, and benign prostatic hyperplasia. The company's lead product, Ekobi, is a biodegradable embolic agent used in minimally invasive treatments to selectively block blood supply to target tissues. IMBiotechnologies aims to improve patient outcomes and quality of life through their advanced medical solutions.Explore more
IMBiotechnologies Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is IMBiotechnologies your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if IMBiotechnologies has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once IMBiotechnologies has new funding data
Product Launch: Get notified when IMBiotechnologies launches new products
Click to see if IMBiotechnologies had a recent Job posting/layoffs
Check out if IMBiotechnologies is spiking on competitors!
IMBiotechnologies, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on IMBiotechnologies recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at IMBiotechnologies
Recommended Actions
Find VP level buyers at IMBiotechnologies
Find 3 more new buyers
Compare Similar Companies to IMBiotechnologies
Compare insights from companies similar to IMBiotechnologies, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
IMBiotechnologies is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
IMBiotechnologies is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about IMBiotechnologies.
IMBiotechnologies Tech Stack
A closer look at the technologies used by IMBiotechnologies
See more technologies
IMBiotechnologies News & Media
IMBiotechnologies Ltd. Announces Agreement with Canadian Hospital Specialties to Distribute Ekobi® Embolization Microspheres in Canada
EDMONTON, Alberta--(BUSINESS WIRE)-- #AlbertaTech--IMBiotechnologies Ltd. Announces Agreement with Canadian Hospital Specialties to Distribute Ekobi® Embolization Microspheres in CanadaIMBiotechnologies Ltd. Expands Approval for EkobiTM Embolization Microspheres to Include Treatment of Uterine Fibroids
EDMONTON, Alberta--(BUSINESS WIRE)--IMBiotechnologies Ltd. (“IMB” or the “Company”) today announced that it has received approval from Heath Canada to expand the indications of its lead product, EkobiTM Embolization Microspheres (“Ekobi”), to include treatment of uterine fibroids. Uterine fibroids are a significant women’s health issue; by the age of 50, 70% of women will develop uterine fibroids; up to 50% of uterine fibroids are symptomatic requiring treatment. Symptoms include abnormal uteriIMBiotechnologies Ltd. Receives Health Canada Approval for a New Biodegradable Embolic Agent
EDMONTON, Alberta--(BUSINESS WIRE)--IMBiotechnologies Ltd. (“IMB” or the “Company”) today announced that it has received Heath Canada approval for its lead product, Ekobi™ Embolization Microspheres (“Ekobi”), for the treatment of hypervascularized tumors (“HVT”) and benign prostatic hypertrophy/hyperplasia (“BPH”). The Ekobi™ product is a patented “first-in-class” embolic therapeutic medical device that provides an alternative to surgery. Ekobi™ is the first and only biodegradable embolic agentIMBiotechnologies Ltd Announces Presentation at the 2018 Cardiovascular and Interventional Radiological Society of Europe Annual Meeting (Lisbon, Portugal)
EDMONTON, Alberta--(BUSINESS WIRE)--IMBiotechnologies Ltd. today announced that an oral presentation regarding the use of its lead product, Occlusin® 500 Embolization Microspheres (Occlusin 500), in benign prostatic hypertrophy (BPH) patients will be presented at the 2018 Cardiovascular and Interventional Radiological Society of Europe (CIRSE) annual meeting. Dr. Richard Owen, lead investigator of the clinical study conducted at the University of Alberta Hospital, will be presenting qualitative
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding IMBiotechnologies
Sign Up For FreeTo access detailed company insights
IMBiotechnologies Ltd. is a Canadian medical device company based in Edmonton, Alberta, specializing in the commercialization of innovative products for embolotherapy. Their core technology focuses on treating solid malignant tumors and benign tumors, including liver cancer, kidney cancer, uterine fibroids, and benign prostatic hyperplasia. The com... Read More
